Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis

Drug Metabolism and Disposition

Volumn 34, Issue 7, 2006, Pages 1122-1127

  Dong, Huan ^a   Suzuki, Naomi ^a   Torres, Maria C ^a   Bonala, Radha R ^a   Johnson, Francis ^a   Grollman, Arthur P ^a   Shibutani, Shinya ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; ARISTOLOLACTAM; BIOLOGICAL MARKER; DNA; NUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARISTOLOCHIACEAE; ARTICLE; BIOTRANSFORMATION; CARCINOGENICITY; CHEMICAL REACTION; CONTROLLED STUDY; DNA ADDUCT; DRUG EFFECT; DRUG STRUCTURE; FORESTOMACH; KIDNEY DISEASE; KIDNEY PARENCHYMA; MALE; NEPHROTOXICITY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; ARISTOLOCHIC ACIDS; BIOLOGICAL MARKERS; DNA; DNA ADDUCTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; INTESTINES; KIDNEY; LIVER; MALE; MUTAGENS; OLIGONUCLEOTIDES; PHOSPHORUS RADIOISOTOPES; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS;

ARISTOLOCHIACEAE; RATTUS NORVEGICUS;

EID: 33745236876     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008706     Document Type: Article

References (35)

1. Arlt VM, Stiborova M, and Schmeiser HH (2002) Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17:265-277.
2. 32P-Post-labeling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18:1063-1067.
3. Cosyns JP (2003) Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug Saf 26:33-48.
4. Cosyns JP, Goebbels RM, Liberton V, Schmeiser HH, Bieler CA, and Bernard AM (1998) Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Arch Toxicol 72:738-743.
5. Cosyns JP, Jadoul M, Squifflet JP, Wese FX, and van Ypersele DS (1999) Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 33:1011-1017.
6. Debelle FD, Nortier JL, De Prez EG, Garbar CH, Vienne AR, Salmon IJ, Deschodt-Lanckman MM, and Vanherweghem JL (2002) Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 13:431-436.
7. Depierreux M, Van Damme B, Van den Houte K, and Vanherweghem JL (1994) Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 24:172-180.
8. Dumić A (1954) Horse Poisoning with Aristolochia clematitis (in Croatian), pp 3-45, Izdanje Vojno tehnićkog glasnika, Zagreb.
9. 32P-postlabeling methods in urothelium and exfoliated cells in urine of rats treated with aristolochic acid I. Carcinogenesis 13:1835-1839.
10. 32P-postlabeling in target and non-target organs of rats treated with aristolochic acid I. IARC Sci Pub 124:167-171.
11. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (2002) Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene, volume 82, pp 69-129, IARC Press, Lyon, France.
12. Krumbiegel G, Hallensleben J, Mennicke WH, Rittmann N, and Roth HJ (1987) Studies on the metabolism of aristolochic acids I and II. Xenobiotica 17:981-991.
13. Kumar V, Poonam, Prasad AK, and Parmar VS (2003) Naturally occurring aristolactams, aristolochic acids and diaxoaporphines and their biological activities. Nat Prod Rep 20:565-583.
14. Li X and Wang H (2004) Aristolochic acid nephropathy: what we know and what we have to do. Nephrology (Carlton) 9:109-111.
15. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, and Schmeiser HH (2004) DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 43:e11-e17.
16. Mengs U (1987) Acute toxicity of aristolochic acid in rodents. Arch Toxicol 59:328-331.
17. Mengs U, Lang W, and Poch JA (1982) The carcinogeneic action of aristolochic acid in rats. Arch Toxicol 51:107-119.
18. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, et al. (2000) Urothelial carcinoma associated with the use of a Chinese herb (aristolochia fangchi). N Engl J Med 342:1686-1692.
19. Pfau W, Schmeiser HH, and Wiessler M (1990a) Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 11:313-319.
20. 32P-Postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 11:1627-1633.
21. Pohl J (1892) Ueber das Aristolochin, einen giftigen Bestandheil der Aristolochia-Arten. Arch Exp Path Pharm 282-301.
22. Poirer MC, Santella RM, and Weston A (2000) Carcinogen macromolecular adducts and their measurement. Carcinogenesis 21:353-359.
23. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7:1543-1551.
24. Sato N, Takahashi D, Chen SM, Tsuchiya R, Mukoyama T, Yamagata S, Ogawa M, Yoshida M, Kondo S, Satoh N, et al. (2004) Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol 56:221-229.
25. 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis 18:1055-1062.
26. Schmeiser HH, Janssen JW, Lyons J, Scherf HR, Pfau W, Buchmann A, Bartram CR, and Wiessler M (1990) Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res 50:5464-5469.
27. Schmeiser HH, Scherf HR, and Wiessler M (1991) Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Lett 59:139-143.
28. Schmeiser HH, Schoepe KB, and Wiessler M (1988) DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9:297-303.
29. 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15:1187-1192.
30. Stiborova M, Frei E, Breuer A, Bieler CA, and Schmeiser HH (1999) Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Exp Toxicol Pathol 51:421-427.
31. Stiborova M, Frei E, Hodek P, Weissler M, and Schmeiser HM (2005) Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 113:189-197.
32. Stiborova M, Frei E, Sopko B, Sopkova K, Markova V, Lankova M, Kumstyrova T, Wiessler M, and Schmeiser HH (2003) Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 24:1695-1703.
33. Stiborova M, Frei E, Sopko B, Wiessler M, and Schmeiser HH (2002) Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23:617-625.
34. Stiborova M, Frei E, Wiessler M, and Schmeiser HH (2001) Human cytochrome P450 enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by CYP1A1 and CYP1A2. Chem Res Toxicol 14:1128-1137.
35. 32P- Postlabeling/polyacrylamide gel electrophoresis analysis: application to the detection of DNA adducts. Chem Res Toxicol 15:305-311.